10 mg Semaglutide: Where This Dose Sits in the Wegovy Schedule

Step 1: Understanding the licensed Wegovy dose range

Wegovy is a once-weekly subcutaneous injection of semaglutide, made by Novo Nordisk and licensed in the UK by the MHRA for weight management in adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition. Its dose ladder is fixed: 0.25 mg for the first four weeks, then 0.5 mg, then 1.0 mg, then 1.7 mg, reaching the 2.4 mg maintenance dose at around week 17. The starting 0.25 mg dose exists to let your body adjust gradually, it is a tolerability step, not a therapeutic target.

In January 2026, the MHRA approved a higher 7.2 mg maintenance dose, and a dedicated single-dose 7.2 mg pen was approved in April 2026 for adults with a BMI of 30 or above. That is the highest licensed semaglutide dose for weight management in the UK. There is no 10 mg step. If a website or supplier is offering semaglutide at 10 mg as a weight-loss treatment, it is not a licensed UK medicine, and that matters enormously when the product in question is an injectable.

The NHS medicines page for semaglutide sets out the approved schedule clearly and is a reliable first check for anyone uncertain about which doses actually exist.

Step 2: Where the 10 mg figure actually comes from

A question our prescribers hear most weeks is some version of: "I read about a 10 mg semaglutide, is that stronger?" The short answer is that 10 mg semaglutide appears in two distinct, non-clinical contexts. The first is peptide research: semaglutide, as a synthetic peptide, is studied in laboratory and preclinical settings where concentrations or masses are expressed in milligrams per vial rather than per weekly dose. The second is the compounded or grey-market injectable market, where products may be sold in vials labelled by total peptide content (for example, a 10 mg multi-dose vial) rather than per-dose concentration.

Neither context has anything to do with Wegovy as a licensed medicine. Compounded semaglutide peptides are not assessed for quality, potency or sterility by the MHRA. They do not go through the same pharmacovigilance process as the branded product. The MHRA has issued repeated public warnings about unlicensed injectable GLP-1 products, and the risks include contamination, incorrect dosing and undisclosed ingredients.

If you are trying to understand what a legitimate semaglutide dose looks like for weight management, the semaglutide peptide dose guide covers the licensed schedule in full detail.

Step 3: Why dose decisions belong with a prescriber

Even within the licensed schedule, deciding how quickly to titrate (or whether to stay at a lower dose for longer) is a clinical call. Some people find 1.7 mg is the dose where side effects settle and appetite suppression feels manageable; others tolerate the full 2.4 mg well from the outset. The STEP 1 trial, published in the New England Journal of Medicine, reported an average weight reduction of around 15% over 68 weeks at 2.4 mg, but individual responses varied considerably. More milligrams does not automatically mean more weight loss for every person, it means more exposure to the drug, and with that comes a higher likelihood of gastrointestinal side effects including nausea, vomiting and diarrhoea.

This is why the 5 mg semaglutide context page and similar resources keep returning to the same point: the number on the pen matters less than whether the dose is right for you, reviewed regularly by a real prescriber. At nume, at nume, our clinical team reviews every consultation personally. No algorithm decides your dose. If you are exploring your options, the weight-loss treatments page outlines how that process works.

For anyone already on Wegovy and thinking about what higher doses involve, the 10 mg semaglutide peptide context page and the broader 10 mg of semaglutide guide address the research and compounding landscape in more detail. And if you are at an earlier stage and wondering how the programme begins, the 1 mg semaglutide page explains the middle of the titration schedule.

Step 4: What to do if you have seen unlicensed semaglutide offered online

Unlicensed injectable peptides sold online under names like "semaglutide 10 mg" or "semaglutide peptide vial" fall outside any UK regulatory framework. That is not a technicality, it means no one has verified what is actually in them. In the most serious cases, fake injectable products have contained insulin, which can cause life-threatening hypoglycaemia in someone who does not have diabetes.

The right response if you encounter these products is to report them to the MHRA via the Yellow Card scheme, which accepts reports of both adverse reactions and suspect medicines. You can also verify whether an online pharmacy is GPhC-registered at the GPhC register. For context on what legitimate private pricing looks like, the weight-loss overview covers the full picture.

The only safe route to semaglutide for weight management is a valid prescription following a clinical assessment by a registered prescriber, dispensed by a pharmacy you can look up on the GPhC register. If you would like to understand whether Wegovy could be suitable for you, speaking to our prescribers is the straightforward next step.